Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27492383 | 0.92 | OPRD1 (0.53) | OPRD1FNTAFNTBPGGT1BAGTR1 | |
| SCHEMBL12914544 | 0.92 | OPRD1 (0.53) | OPRD1FNTAFNTBPGGT1BAGTR1 | |
| SCHEMBL952096 | 0.85 | OPRD1 (0.56) | OPRD1FNTAFNTBPGGT1BAGTR1 | |
| SCHEMBL646710 | 0.76 | SLC6A2 (0.54) | AGTR1AGTR2NMUR2NMUR1 | |
| SCHEMBL12914542 | 0.76 | CASP1 (0.48) | — | |
| SCHEMBL949169 | 0.76 | CASP1 (0.48) | — | |
| SCHEMBL12914540 | 0.76 | SLC6A2 (0.54) | AGTR1AGTR2NMUR2NMUR1 | |
| SCHEMBL14369994 | 0.76 | OPRM1 (0.45) | — | |
| SCHEMBL12914510 | 0.76 | OPRM1 (0.45) | — | |
| SCHEMBL14369995 | 0.76 | OPRM1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | OPRD1 3475/4885FNTA 1710/4885FNTB 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.